Ignite Creation Date:
2024-05-05 @ 7:56 PM
Last Modification Date:
2024-10-26 @ 9:55 AM
Study NCT ID:
NCT00761384
Status:
COMPLETED
Last Update Posted:
2016-02-19
First Post:
2008-09-26
Brief Title:
High Dose Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells PBSC Support in B-cell Lymphoma
Sponsor:
Lund University Hospital
Organization:
Lund University Hospital
Study Overview
Official Title:
A Prospective Study With Individually Adjusted High Dose 90Y-Ibritumomab Tiuxetan Treatment With Peripheral Blood Stem Cells Support to Improve Outcome for Patients With RefractoryRecurrent B-cell Lymphoma Stage II-IV
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HITT
Brief Summary:
90Y-ibritumomab given with stem cells support based on absorbed dose escalation to the liver Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT number 2007-002762-35 | None | None | None |